0001209191-19-053286.txt : 20191016 0001209191-19-053286.hdr.sgml : 20191016 20191016162023 ACCESSION NUMBER: 0001209191-19-053286 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191014 FILED AS OF DATE: 20191016 DATE AS OF CHANGE: 20191016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lloyd-Smith Malcolm CENTRAL INDEX KEY: 0001557146 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 191152965 MAIL ADDRESS: STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-14 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001557146 Lloyd-Smith Malcolm 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Regulatory Officer Common Stock 2019-10-14 4 M 0 9956 15.45 A 29569 D Common Stock 2019-10-14 4 S 0 9956 90.8484 D 19613 D Non-Qualified Stock Option 15.45 2019-10-14 4 M 0 9956 15.45 D 2024-10-01 Common Stock 9956 0 D Includes a total of 375 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 190 shares were purchased on February 28, 2019 and 185 shares were purchased on August 30, 2019. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.70 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted October 1, 2014 and vested at 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015. /s/ Darin Lippoldt, Attorney-in-Fact 2019-10-16